Verified July 2026 · Cited to primary sources
Peptides marketed for immune function, graded by human evidence and legal status. Thymosin alpha-1 has the strongest human evidence, an approved drug in dozens of countries (though not the US); the rest are earlier-stage or antimicrobial.
Evidence for this goal
Thymosin alpha-1 (Grade B) has the most human data, approved outside the US for hepatitis and studied as a sepsis and immune adjunct. LL-37 (Grade C) is an antimicrobial peptide with one small positive trial and one failed larger trial. VIP (Grade C) and KPV (Grade D) are earlier-stage. None is FDA-approved in the US.
How to read this comparison
Compounds are listed alphabetically, not ranked for this goal. The overall grade reflects the evidence described in each record. Evidence for one condition, population or product form does not establish benefit for every use. Affiliate availability never changes a grade.
A historical FDA survey of compounded drugs found 31% failed standard potency testing. What is actually in the vial is a separate question from whether the compound works, and a rubric like this exists to keep the two apart. See the full A to F methodology →
Evidence scope: Grade D: preclinical only (cell and animal colitis models), no published human RCT (rule 5 fired).
Sources: FDA PCAC July 23-24, 2026 meeting (docket) · RAPS: FDA advisory committee backs controversial peptides (July 23, 2026 vote coverage) · Federal Register FDA-2025-N-6895 (April 2026 503A reclassification)
Anti-inflammatory tripeptide that suppresses NF-κB and pro-inflammatory signaling. Studied for gut and skin inflammation.
KPV is not FDA-approved and is not yet legal to compound. On July 23, 2026 the FDA's PCAC panel voted 8 to 6 (1 abstention) to recommend adding it to the 503A list for wound healing and inflammatory conditions, overriding the FDA's own scientists, but the FDA still decides and has not acted. Human evidence stays Grade D: cell and animal anti-inflammatory data only, no human trials.
See the evidence →Evidence scope: There is real human trial data, which keeps it above animal-only, but the results are genuinely mixed. A small first-in-man phase 1/2a study (n=34) in venous leg ulcers found lower doses of topical LL-37 healed several-fold faster than placebo. But the larger, better-powered phase 2b multicentric RCT (n=148) was NEGATIVE for the overall population, with only a post-hoc signal in patients with large ulcers. So the honest read is: a positive small trial, a failed larger trial, and a subgroup hint that needs confirming. That is a small-human-pilot picture with a caution flag, not proof of efficacy.
Sources: LL-37 for hard-to-heal venous leg ulcers: randomized, placebo-controlled phase 1/2a trial, n=34 (Wound Repair Regen, 2014) · Evaluation of LL-37 in hard-to-heal venous leg ulcers: multicentric randomized placebo-controlled phase 2b trial, n=148 (negative primary endpoint) (Wound Repair Regen, 2021)
LL-37 is the only human cathelicidin, released from a precursor protein (hCAP-18) by immune and skin cells. It punches holes in bacterial membranes to kill microbes directly, but it does more than that: it neutralizes bacterial toxins, recruits immune cells, promotes new blood vessel growth, and drives the migration of skin cells that close wounds. Those wound-healing and immune-signaling roles, not just the antibacterial action, are why it gets studied as a topical for hard-to-heal ulcers.
An interesting molecule with an honest evidence problem. Because it is the body's own antimicrobial peptide with plausible wound-healing biology, it draws attention, and there is a positive small human trial. But the larger, more rigorous trial did not confirm it, which is exactly the pattern you should respect rather than explain away. Grade C, and specifically the kind of C where the definitive data leaned negative. Not something to self-inject, and the wound-healing story is unproven, not promising-and-confirmed.
See the evidence →Evidence scope: Approved as a prescription drug in roughly 35 countries (hepatitis B/C, immune support) and backed by multiple randomized human trials. The ETASS multicenter RCT (n=361) in severe sepsis showed a 9% absolute drop in 28-day mortality (26.0% vs 35.0%), though it just missed statistical significance (p=0.062). A systematic review of RCTs found a significant mortality benefit in sepsis (RR 0.59). The catch: trials are mostly China-based, quality is graded low-to-moderate, and it is NOT FDA-approved. So the human evidence is real and multi-trial (well above animal-only), but not a clean US-approved A.
Sources: ETASS: thymosin alpha 1 for severe sepsis, multicenter RCT, n=361 (Critical Care, 2013) · Thymosin alpha1 as immunomodulatory treatment for sepsis: systematic review of RCTs (BMC Infectious Diseases, 2016) · Thymosin alpha 1: a comprehensive review of the literature (World Journal of Virology, 2020)
Synthetic copy of a peptide the thymus makes naturally. It signals through Toll-like receptors (mainly TLR9 and TLR2) on dendritic cells and immune cells, which pushes maturation of T cells, boosts natural killer cell activity, and shifts the immune response toward a Th1 (antiviral, antitumor) pattern. It is an immune tuner rather than a straight stimulant, so it gets studied in both underactive immunity (infection, sepsis) and settings where you want a stronger antiviral or antitumor response.
The strongest immune peptide in this group on human evidence. It is a genuine approved drug in dozens of countries with real randomized-trial support in sepsis and hepatitis, which is why it grades a B. But it never cleared the FDA, so in the US it is research-only, and the sepsis mortality signal, while promising, has not been confirmed in a definitive Western trial. If you want an immune peptide with actual clinical pedigree, this is it, but treat US-sourced material with skepticism and do not use it to self-treat serious illness.
See the evidence →Evidence scope: Genuinely mixed, and the mix lands at C. On the plus side, VIP combined with phentolamine (Invicorp) is an approved erectile-dysfunction drug in parts of Europe, and there is a large body of human physiology behind the peptide. On the minus side, its highest-profile modern program failed: the phase 3 TESICO trial (n=461) of intravenous aviptadil for COVID-19 hypoxemic respiratory failure was clearly NEGATIVE (odds ratio 1.11, p=0.54; no mortality benefit), and the FDA declined Emergency Use Authorization for aviptadil in November 2021 citing insufficient data. So: real approved use for one narrow indication abroad, but the marquee respiratory indication was tested at scale and failed. That honest tension is a C, not the promising story vendors imply.
Sources: TESICO: intravenous aviptadil and remdesivir for COVID-19 hypoxaemic respiratory failure, randomized placebo-controlled trial, n=461 (NEGATIVE primary endpoint) (Lancet Respir Med, 2023) · FDA declines Emergency Use Authorization for ZYESAMI (aviptadil) for critical COVID-19 with respiratory failure, November 2021
VIP is a widely distributed neuropeptide that acts through VPAC1 and VPAC2 receptors. It relaxes smooth muscle (blood vessels and airways), has anti-inflammatory and immune-modulating effects, and in the lung it supports surfactant production and protects certain lung cells. Aviptadil is the synthetic form of VIP. Those lung-protective and vasodilatory properties are the rationale behind trialing it in respiratory failure, pulmonary hypertension, and (combined with phentolamine, as Invicorp) erectile dysfunction.
A natural peptide that got a very public shot at the big time and largely missed. VIP itself has real physiology and one approved niche use abroad (erectile dysfunction), which keeps it out of the failed-entirely bin. But the aviptadil respiratory story is the important one, and it was tested properly in a phase 3 trial and did not work, and the FDA declined authorization. Grade C, weighted toward the sobering side. If someone is selling you aviptadil for lung health or recovery, the definitive human trial already said no.
See the evidence →| Peptide | Overall grade | Legal & safety | Typical cost | Verdict | |
|---|---|---|---|---|---|
| KPV An anti-inflammatory tripeptide studied for gut and skin inflammation. Promising in cells and animals, untested in humans. | Grade D | See evidenceSee the evidence for KPV | |||
| LL-37 (Cathelicidin) The body's own 37-amino-acid antimicrobial peptide. It has genuine human wound-healing trials, but the largest one (phase 2b) failed its main endpoint, so the evidence is a mixed, small-scale C. | Grade C | See evidenceSee the evidence for LL-37 (Cathelicidin) | |||
| Thymosin Alpha-1 A 28-amino-acid thymic peptide that tunes the immune system. Approved as a drug (Zadaxin) in ~35 countries for hepatitis and immune support, but never FDA-approved, so in the US it is research-only. | Grade B | See evidenceSee the evidence for Thymosin Alpha-1 | |||
| VIP (Vasoactive Intestinal Peptide / Aviptadil) A natural 28-amino-acid neuropeptide with broad signaling roles. Its big FDA push (aviptadil for COVID) failed a phase 3 trial and the FDA declined authorization, so the evidence is a mixed C. | Grade C | See evidenceSee the evidence for VIP (Vasoactive Intestinal Peptide / Aviptadil) |
Reading this table: Grades refer to each compound's stated evidence scope, not every use in this category. Legal status and Safety are separate badges; Verdict is the compound summary. Affiliate availability never changes a grade. Full methodology.
FAQ
Thymosin alpha-1 has the most human evidence (Grade B). It is approved in dozens of countries for hepatitis B and C and studied as an adjunct in sepsis and immune dysfunction, though it is not FDA-approved in the US. LL-37 (Grade C) is antimicrobial but its evidence is mixed.
Not in the United States. Thymosin alpha-1 (Zadaxin) is approved in roughly 35 countries for hepatitis B, hepatitis C and as an immune adjunct, and it has real human trials, but the FDA has not approved it, so in the US it is research-only.
It depends on the peptide. Thymosin alpha-1 has genuine clinical trials behind it (Grade B). Most others (KPV, injectable thymosin beta-4) are Grade C or D: promising mechanisms but thin or no human efficacy data. Be skeptical of any vendor promising an immune miracle.
Read the evidence
Before you buy anything
Other goals
The monthly peptide evidence brief.
What the research and the FDA actually say, in one short email a month. Unsubscribe anytime.
No spam. We never sell your email. Editorial policy.